Physician profile
Himanshu Suri
NPI 1073977328
$25,485.83
in general payments reported to CMS, 2019-2025
23 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 78% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.61 · 2020: $206 · 2021: $21K · 2022: $944 · 2023: $906 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,162.16 | 2021-2025 | Intracept, General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $10,331.61 | 2021-2022 | |
| Nalu Medical, INC. | $782.59 | 2025 | Nalu Neurostimulation System |
| Nevro Corp. | $383.54 | 2021-2023 | Senza |
| Scilex Pharmaceuticals INC. | $346.60 | 2022-2023 | Ztlido |
| Spr Therapeutics, INC | $222.30 | 2021 | |
| Abbott Laboratories | $220.32 | 2021 | |
| Merz North America, INC. | $132.74 | 2020 | |
| Allergan, INC. | $130.76 | 2019-2021 | |
| Forte Bio-Pharma LLC | $121.98 | 2023 | Prolate, Nalocet |
| Vertos Medical, INC. | $112.22 | 2022 | |
| Spinal Simplicity, LLC | $105.51 | 2023 | Ha Minuteman G3-R |
| Collegium Pharmaceutical, INC. | $64.48 | 2023 | Xtampza |
| Amneal Pharmaceuticals LLC | $56.55 | 2021 | |
| Sunovion Pharmaceuticals INC. | $52.11 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $49.34 | 2023 | |
| Acorda Therapeutics, INC | $47.19 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.23 | 2023 | Relistor |
| Abbvie INC. | $45.14 | 2023 | Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $19.78 | 2023 | Austedo |
| Avanir Pharmaceuticals, INC. | $19.19 | 2020 | |
| Redhill Biopharma INC. | $17.33 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himanshu Suri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.